BR0316305A - Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit - Google Patents

Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit

Info

Publication number
BR0316305A
BR0316305A BR0316305-9A BR0316305A BR0316305A BR 0316305 A BR0316305 A BR 0316305A BR 0316305 A BR0316305 A BR 0316305A BR 0316305 A BR0316305 A BR 0316305A
Authority
BR
Brazil
Prior art keywords
animal
composition
compound
treating
methods
Prior art date
Application number
BR0316305-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhengming Chen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BR0316305A publication Critical patent/BR0316305A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0316305-9A 2002-11-18 2003-11-17 Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit BR0316305A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42738102P 2002-11-18 2002-11-18
US46027803P 2003-04-03 2003-04-03
US48848803P 2003-07-17 2003-07-17
US10/714,066 US7202259B2 (en) 2002-11-18 2003-11-13 Therapeutic agents useful for treating pain
PCT/US2003/036742 WO2004046132A1 (en) 2002-11-18 2003-11-17 4-tetrazolyl-4phenylpiperidine derivatives for treating pain

Publications (1)

Publication Number Publication Date
BR0316305A true BR0316305A (pt) 2005-09-27

Family

ID=32777221

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316305-9A BR0316305A (pt) 2002-11-18 2003-11-17 Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit

Country Status (36)

Country Link
US (3) US7202259B2 (https=)
EP (2) EP1562932B9 (https=)
JP (2) JP4601429B2 (https=)
KR (1) KR20050115221A (https=)
CN (2) CN100567288C (https=)
AP (1) AP2210A (https=)
AR (1) AR047008A1 (https=)
AT (2) ATE358674T1 (https=)
AU (2) AU2003294313B2 (https=)
BR (1) BR0316305A (https=)
CA (1) CA2506242C (https=)
CO (1) CO5690588A2 (https=)
CR (2) CR7877A (https=)
CY (2) CY1107682T1 (https=)
DE (2) DE60322451D1 (https=)
DK (2) DK1803718T3 (https=)
EA (1) EA008621B1 (https=)
EC (1) ECSP055840A (https=)
ES (2) ES2285235T3 (https=)
GE (1) GEP20084539B (https=)
IL (1) IL209352A0 (https=)
IS (2) IS2720B (https=)
MA (1) MA27565A1 (https=)
ME (1) MEP48108A (https=)
MX (1) MXPA05004669A (https=)
MY (1) MY135647A (https=)
NI (1) NI200500087A (https=)
NO (1) NO20052894L (https=)
NZ (2) NZ572685A (https=)
OA (1) OA13010A (https=)
PT (2) PT1562932E (https=)
RS (1) RS51047B (https=)
SG (1) SG165998A1 (https=)
SI (2) SI1803718T1 (https=)
TW (2) TWI343917B (https=)
WO (1) WO2004046132A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
KR101159828B1 (ko) 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
CA2552087C (en) 2004-01-30 2011-01-25 Euro-Celtique S.A. Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SI1951718T1 (sl) * 2005-11-21 2012-06-29 Purdue Pharma Lp 4-oksadiazolil-piperidinske spojine in njihova uporaba
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
ME02367B (me) 2010-09-21 2016-06-20 Purdue Pharma Lp Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora
CN102648915B (zh) * 2011-02-28 2015-04-15 鲁南制药集团股份有限公司 一种治疗或预防神经病理性疼痛的药物组合物
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CA2890655A1 (en) 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US9175000B2 (en) 2012-12-07 2015-11-03 Purdue Pharma L.P. Buprenorphine analogs
ES2631197T3 (es) 2012-12-14 2017-08-29 Purdue Pharma Lp Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
EP2931726B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Spirocyclic morphinans and their use
WO2014118618A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9340542B2 (en) 2013-12-26 2016-05-17 Purdue Pharma L.P. Propellane-based compounds and the use thereof
EP3087057A4 (en) 2013-12-26 2017-06-28 Purdue Pharma LP Ring-contracted morphinans and the use thereof
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
US9994571B2 (en) 2013-12-26 2018-06-12 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
US10030021B2 (en) 2014-05-27 2018-07-24 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
EP3154972A4 (en) 2014-06-13 2017-11-22 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
AU2017238208B2 (en) 2016-03-22 2022-01-06 Regents Of The University Of Minnesota Combination for treating pain
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
CN117750958A (zh) * 2021-05-21 2024-03-22 普渡制药公司 治疗间质性膀胱炎/膀胱疼痛综合征的方法
CA3258088A1 (en) * 2022-06-24 2023-12-28 Purdue Pharma L.P. METHODS OF TREATMENT OR PREVENTION OF OVERACTIVE BLADDER SYNDROME

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
BE775611A (fr) 1970-11-24 1972-03-16 Synthelabo Derives de la (diphenyl-3,3 propyl-1)-1 piperidine, leur preparation etles medicaments qui en contiennent
US4076717A (en) * 1971-12-15 1978-02-28 G. D. Searle & Co. Derivatives of 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US4831192A (en) * 1987-12-31 1989-05-16 Boc, Inc. Methods of preparing 4-heteropentacyclic-4-(N-phenyl)amido) piperidine derivatives and intermediate compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5449989A (en) 1992-07-31 1995-09-12 Correa; Paulo N. Energy conversion system
US5736523A (en) 1992-11-09 1998-04-07 Biochem Pharma Inc. Antineoplastic heteronapthoquinones
US5606037A (en) 1992-11-09 1997-02-25 Biochem Pharma Inc. Processes antineoplastic heteronaphthoquinones
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
US6166085A (en) 1995-04-14 2000-12-26 The Regents Of The University Of California Method of producing analgesia
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
AU3108097A (en) * 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds
EP1058684A1 (en) 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
NZ528846A (en) 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
AU7315800A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Mch antagonists
CA2324330A1 (en) 1999-11-08 2001-05-08 Ssp Co., Ltd. 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
EP1242085B1 (en) 1999-12-06 2005-08-24 Euro-Celtique, S.A. Benzimidazole compounds having nociceptin receptor affinity
US6486142B2 (en) 1999-12-22 2002-11-26 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US6703525B2 (en) 2000-02-16 2004-03-09 Boehringer Ingelheim Pharmaceuticals, Inc. Sulfonamide intermediates and methods of producing same
US6790854B2 (en) 2000-03-24 2004-09-14 Meiji Seika Kaisha, Ltd. Diphenylalkylamine derivatives useful as opioid receptor agonists
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
CN1469862A (zh) 2000-10-12 2004-01-21 Ss制药株式会社 2,2-二苯基丁酰胺衍生物和含有它的药物
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
CA2552087C (en) 2004-01-30 2011-01-25 Euro-Celtique S.A. Methods for making 4-tetrazolyl-4-phenylpiperidine compounds

Also Published As

Publication number Publication date
AU2003294313B2 (en) 2010-08-26
HK1086829A1 (zh) 2006-09-29
MA27565A1 (fr) 2005-10-03
OA13010A (en) 2006-11-10
PT1562932E (pt) 2007-07-02
US20070179141A1 (en) 2007-08-02
IL209352A0 (en) 2011-01-31
JP2006525944A (ja) 2006-11-16
GEP20084539B (en) 2008-11-25
MEP48108A (en) 2011-02-10
KR20050115221A (ko) 2005-12-07
WO2004046132A1 (en) 2004-06-03
AR047008A1 (es) 2006-01-04
CY1108422T1 (el) 2014-04-09
US7687518B2 (en) 2010-03-30
ECSP055840A (es) 2005-08-11
EP1803718A1 (en) 2007-07-04
ATE402167T1 (de) 2008-08-15
ES2312150T3 (es) 2009-02-16
NZ540068A (en) 2007-07-27
CR11037A (es) 2009-10-29
TW200418828A (en) 2004-10-01
CN1711256A (zh) 2005-12-21
MY135647A (en) 2008-06-30
NZ572685A (en) 2010-06-25
CA2506242C (en) 2011-07-05
AP2210A (en) 2011-02-25
DE60313021T2 (de) 2007-12-13
IS8913A (is) 2010-07-21
ES2285235T3 (es) 2007-11-16
CN101648941A (zh) 2010-02-17
US8026254B2 (en) 2011-09-27
IS2720B (is) 2011-02-15
RS51047B (sr) 2010-10-31
DE60322451D1 (de) 2008-09-04
DE60313021D1 (de) 2007-05-16
EA008621B1 (ru) 2007-06-29
EP1562932A1 (en) 2005-08-17
US20100069437A1 (en) 2010-03-18
NO20052894D0 (no) 2005-06-14
EA200500726A1 (ru) 2005-10-27
PT1803718E (pt) 2008-09-26
TW200819436A (en) 2008-05-01
NI200500087A (es) 2007-07-24
NO20052894L (no) 2005-06-14
CO5690588A2 (es) 2006-10-31
JP4601429B2 (ja) 2010-12-22
SG165998A1 (en) 2010-11-29
RS20050375A (sr) 2007-11-15
US20040152689A1 (en) 2004-08-05
DK1803718T3 (da) 2008-10-27
JP2010163452A (ja) 2010-07-29
CR7877A (es) 2005-11-30
AU2010246411A1 (en) 2010-12-16
US7202259B2 (en) 2007-04-10
AP2005003297A0 (en) 2005-06-30
SI1562932T1 (sl) 2007-08-31
AU2003294313A1 (en) 2004-06-15
DK1562932T3 (da) 2007-08-13
CN100567288C (zh) 2009-12-09
MXPA05004669A (es) 2005-06-08
EP1562932B1 (en) 2007-04-04
EP1803718B1 (en) 2008-07-23
CY1107682T1 (el) 2013-04-18
ATE358674T1 (de) 2007-04-15
IS7812A (is) 2005-04-19
EP1562932B9 (en) 2007-09-12
SI1803718T1 (sl) 2008-12-31
TWI343917B (en) 2011-06-21
CA2506242A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
BR0316305A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
CY1109031T1 (el) Τριαζασπιρο ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
MXPA06012500A (es) Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
WO2005011590A3 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
BRPI0417902A (pt) piperazinas úteis no tratamento da dor
BR9915390A (pt) Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
IL126175A0 (en) Method or treating heart failure with endothelin antagonists and pharmaceutical compositions containing the same
IL166596A0 (en) Salt of morphine-6-glucoronide
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
UA86009C2 (ru) 4-тетразолил-4-фенилпиперидиновые производные для лечения боли
TNSN05114A1 (en) 4-tetrazolyl -4 phenylpiperidine derivatives for treating pain
WO2005035500A3 (en) Therapeutic agents useful for treating pain
BRPI0409868A (pt) composição farmacêutica que compreende um inibidor da catepsina s e um opióide
UA4486U (uk) Препарат "глютам-1м" для стимуляції запліднюваності самок тварин

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.